Literature DB >> 24728774

Is screening for AF worthwhile? Stroke risk in a screened population from the SAFE study.

D A Fitzmaurice1, D McCahon2, J Baker1, E T Murray1, S Jowett3, H Sandhar1, R L Holder1, F D R Hobbs4.   

Abstract

INTRODUCTION: Atrial fibrillation (AF) is an important independent risk factor for stroke and oral anticoagulation therapy provides a highly effective treatment to reduce this risk. Active screening strategies improve detection of AF in comparison with routine care; however, whether screen-detected patients have stroke risk profiles favouring anticoagulation is unclear. Using data derived from the screening for AF in the elderly (SAFE) study, the aim of this article was to determine if patients with AF detected via active screening have stroke risk profiles that warrant prophylactic anticoagulation.
METHODS: Secondary analysis of data derived from 25 general practices within which cohorts of 200 patients were randomly allocated to opportunistic [pulse and electrocardiogram (ECG)] or systematic screening (postal invitation for ECG). Stroke risk assessment was undertaken using baseline data extracted from medical records and CHADS2 criteria. CHADS2 scores were compared between the screening groups.
RESULTS: One hundred and forty-nine new cases of AF were detected, 75 via opportunistic screening and 74 via systematic screening. CHADS2 scores were ≥1 in 83% [95% confidence interval (CI) 72.6-89.6] of patients detected via opportunistic screening and 78% (95% CI 67.7-86.2) detected via systematic screening. There were no significant differences in stroke risk profiles of patients detected via opportunistic and systematic screenings.
CONCLUSION: Stroke risk profiles of patients detected via opportunistic and systematic screenings were similar. Data derived from the SAFE study suggest that active screening for AF in patients aged ≥65 years in primary care is a useful screening programme with 78-83% of patients identified eligible for anticoagulation treatment according to the CHADS2 criteria.
© The Author 2014. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Anticoagulation; atrial fibrillation; primary care; risk factors; screening; stroke.

Mesh:

Substances:

Year:  2014        PMID: 24728774     DOI: 10.1093/fampra/cmu011

Source DB:  PubMed          Journal:  Fam Pract        ISSN: 0263-2136            Impact factor:   2.267


  6 in total

1.  Stroke prevention in atrial fibrillation: we can do better.

Authors:  Matt Kearney; Matthew Fay; David A Fitzmaurice
Journal:  Br J Gen Pract       Date:  2016-02       Impact factor: 5.386

2.  Research into practice: management of atrial fibrillation in general practice.

Authors:  David A Fitzmaurice; F D Richard Hobbs
Journal:  Br J Gen Pract       Date:  2014-10       Impact factor: 5.386

3.  Yield of screening for atrial fibrillation in primary care with a hand-held, single-lead electrocardiogram device during influenza vaccination.

Authors:  Femke Kaasenbrood; Monika Hollander; Frans H Rutten; Leo J Gerhards; Arno W Hoes; Robert G Tieleman
Journal:  Europace       Date:  2016-02-06       Impact factor: 5.214

Review 4.  European Primary Care Cardiovascular Society (EPCCS) consensus guidance on stroke prevention in atrial fibrillation (SPAF) in primary care.

Authors:  Fd Richard Hobbs; Clare J Taylor; Geert Jan Geersing; Frans H Rutten; Judith R Brouwer
Journal:  Eur J Prev Cardiol       Date:  2015-02-20       Impact factor: 7.804

Review 5.  Screening for atrial fibrillation: a call for evidence.

Authors:  Nicholas R Jones; Clare J Taylor; F D Richard Hobbs; Louise Bowman; Barbara Casadei
Journal:  Eur Heart J       Date:  2020-03-07       Impact factor: 29.983

Review 6.  Screening of older patients for atrial fibrillation in general practice: Current evidence and its implications for future practice.

Authors:  Matthew R Fay; David A Fitzmaurice; Ben Freedman
Journal:  Eur J Gen Pract       Date:  2017-12       Impact factor: 1.904

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.